Ligand Pharmaceuticals Incorporated LGND announces the
signing of global license and supply agreements with Spectrum
Pharmaceuticals, Inc. SPPI for the development and
commercialization of Ligand's Captisol-enabled®, propylene
glycol-free (PG-free) melphalan. Under the terms of the license
agreement, Ligand is entitled to receive a license fee and is eligible
to receive more than $50 million in potential milestone payments. Ligand
is also eligible to receive royalties on future net sales of
Captisol-enabled melphalan. Further details regarding the transaction
are provided in Ligand's Form 8-K that is being filed today.
The Captisol-enabled melphalan program is currently in a pivotal trial
for use as a conditioning treatment prior to autologous stem cell
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in